-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Selpercatinib in Central Nervous System (CNS) Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Selpercatinib in Central Nervous System (CNS) TumorDrug Details: Selpercatinib (Retevmo, Retsevmo) is a potent antineoplastic agent....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Selpercatinib in Small Intestine Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Selpercatinib in Small Intestine CancerDrug Details: Selpercatinib (Retevmo, Retsevmo) is a potent antineoplastic agent. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Selpercatinib in Follicular Thyroid Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Selpercatinib in Follicular Thyroid CancerDrug Details: Selpercatinib (Retevmo, Retsevmo) is a potent antineoplastic agent. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Selpercatinib in Anaplastic Thyroid Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Selpercatinib in Anaplastic Thyroid CancerDrug Details: Selpercatinib (Retevmo, Retsevmo) is a potent antineoplastic agent. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CD19-CAR-T in Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CD19-CAR-T in Lymphoma Drug Details:Gene-modified cell therapy is under development for the treatment of lymphoma. The...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – YTE-001 in Epstein–Barr Virus (HHV-4) Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.YTE-001 in Epstein–Barr Virus (HHV-4) InfectionsDrug Details:Gene therapy is under development for the treatment of Epstein...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DCSZ-11 in Gastric Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DCSZ-11 in Gastric Cancer Drug Details:DCSZ-11 is under development for the treatment of metastatic solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PF-06940434 in Hypopharyngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PF-06940434 in Hypopharyngeal Cancer Drug Details: PF-06940434 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LOX-19260 in Medullary Thyroid Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.LOX-19260 in Medullary Thyroid Cancer Drug Details: LOX-19260 is under development for the treatment of medullary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LOX-19260 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.LOX-19260 in Solid Tumor Drug Details: LOX-19260 is under development for the treatment of medullary thyroid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ozuriftamab Vedotin in Hypopharyngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ozuriftamab Vedotin in Hypopharyngeal Cancer Drug Details: BA-3021 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Larotrectinib Sulfate in Thyroid Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Larotrectinib Sulfate in Thyroid Cancer Drug Details: Larotrectinib Sulfate (Vitrakvi) is a anti-neoplastic agent. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Larotrectinib Sulfate in Glioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Larotrectinib Sulfate in Glioma Drug Details:Larotrectinib Sulfate (Vitrakvi) is a anti-neoplastic agent. It is formulated as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Larotrectinib Sulfate in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Larotrectinib Sulfate in Non-Small Cell Lung Cancer Drug Details: Larotrectinib Sulfate (Vitrakvi) is a anti-neoplastic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Larotrectinib Sulfate in Neuroblastoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Larotrectinib Sulfate in Neuroblastoma Drug Details:Larotrectinib Sulfate (Vitrakvi) is a anti-neoplastic agent. It is formulated as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Larotrectinib Sulfate in Sarcomas
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Larotrectinib Sulfate in Sarcomas Drug Details:Larotrectinib Sulfate (Vitrakvi) is a anti-neoplastic agent. It is formulated as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Larotrectinib Sulfate in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Larotrectinib Sulfate in Ovarian Cancer Drug Details: Larotrectinib Sulfate (Vitrakvi) is a anti-neoplastic agent. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Larotrectinib Sulfate in Fibrosarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Larotrectinib Sulfate in FibrosarcomaDrug Details:Larotrectinib Sulfate (Vitrakvi) is a anti-neoplastic agent. It is formulated as solution...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Larotrectinib Sulfate in Soft Tissue Sarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Larotrectinib Sulfate in Soft Tissue Sarcoma Drug Details:Larotrectinib Sulfate (Vitrakvi) is a anti-neoplastic agent. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Larotrectinib Sulfate in Pediatric Diffuse Intrinsic Pontine Glioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Larotrectinib Sulfate in Pediatric Diffuse Intrinsic Pontine GliomaDrug Details:Larotrectinib Sulfate (Vitrakvi) is a anti-neoplastic agent. It...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.